Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Breast 3Gynecologic 2

Conditions

Breast Neoplasms 161Neoplasm Metastasis 22Neoplasms 20Advanced Breast Cancer 13Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Hereditary Sensory and Autonomic Neuropathies 9Endometrial Neoplasms 8Triple Negative Breast Neoplasms 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Recurrence 4Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Breast Diseases 4Small Cell Lung Carcinoma 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Neoplasms 2Stomach Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Liposarcoma 2HER2-positive Metastatic Breast Cancer 2Advanced Solid Tumors 2Advanced Solid Tumor 2Urologic Neoplasms 1

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × Fulvestrant × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06993844 2026-05-06

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Ensem Therapeutics

Phase 1/2 Recruiting
233 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Pfizer

Phase 2 Active not recruiting
35 enrolled
BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡